Experimental study of the effectiveness of the removal of virus hepatitis B, C and parvovirus B19 by the fractionation of blood plasma with ethanol

The purpose of the study was to assess the effectiveness of the removal of nucleic acids (NA), Hepatitis B (HBV) and C (HCV) viruses and parvovirus B19 (B19V) from blood plasma fractions obtained by alcohol separation. The studies were performed in a model experiment by fractionation normal pool plasma donation contaminated with virus-containing samples in the laboratory. It was found that the multi-step process to extract a fraction II, designed to provide the immunoglobulin G, provided the elimination of NA HBV and HCV to undetectable levels by PCR, and the total reduction factor compared to the original composition of the plasma HBV DNA >5.35 log_, HCV RNA >4.84 log. Factor DNA V19V reduction was at the level of 4.56 log(CI 4.49-4.63). Upon receipt of the fraction V (for albumin) reduction factor of the test virus was >3.0 log wich in combination with additional purification step provides a reliable level of safety. The selection fraction I resulted in effectiveness of the elimination of HBV DNA and V19V DNA less than 2 orders, HCV RNA - less than 3 orders of magnitude, it is not enough to recognize the stage reliable. Experiments confirmed that the high risk of contamination of production pools parvovirus B19 additional safety measures are necessary, including mandatory investigation of plasma DNA V19V. In general the development of a full cycle of drug from blood plasma from donors, basic process alcohol fractionation steps necessary to supplement validation virus elimination and inactivation considering residual risk of contamination with pathogenic agents feedstock.

препараты из плазмы крови, фракции плазмы, вирусная безопасность, спиртовое фракционирование, инактивация вирусов, нуклеиновые кислоты, концентрация вирусов (С), вирусная нагрузка (VL), фактор редукции (RF), drugs from blood plasma, plasma fractions, viral safety, alcohol fractionation, viral inactivation, nucleic acids, virus concentration (С), viral load (VL), the reduction factor (RF)

1. Burnouf T. Modern plasma fractionation.Transfus Med Rev. 2007; 21(2): 101–17.

2. CPMP/BWP/268/95 Virus Validation Studies: the design contribution and interpretation of studies validating the inactivation and removal of viruses. European Medicines Agency. Available from: http://www.ema.europa.eu/docs/en GB/document_library/Scientific_guideline/2009/09/WC500003684.pdf.

3. Zubkova NV. Ensuring of the infectious safety of plasma blood preparations. Gematologiya i transfuziologiya 2014; (2): 44–9 (in Russian).

4. State Standard. General Pharmacopeia article «Human blood plasma derived drugs». Ministry of health order ¹ 768 dated 21.11.2014. Available from: http://www.rosminzdrav.ru/ministry/61/11/materialy-po-deyatelnosti-deparatamenta/stranitsa856/ (in Russian).

5. WHO Guidance document on viral inactivation and removal procedure intended to assure the viral safety of blood plasma products. WHO Technical Report, Series ¹ 924, Annex 4. 2004. Available from: http://www.who.int/bloodproducts/publications/WHO_ TRS_924_A4.pdf?ua=1.

6. Dichtelmüller H, Flechsig E, Sananes F, Kretschmar M, Dougherty C. Effective virus inactivation and removal by steps of Biotest Pharmaceuticals IGIV production process. Results in Immunology 2012; (2): 19–24.

7. Jeong HS, Shin JH, Park YN, Choi JY, Kim YL, Kim BG et al. Development of real-time RT-PCR for evaluation of JEV clearance during purification of HPV type 16 L1 virus-like particles. Biologicals 2003; 31(3): 223–9.

8. Blümel J, Burger R, Drosten C, Gröner A, Gürtler L, Heiden M et al. Parvovirus B19-Revised. Transfus Med Hemother. 2010; 37(6): 339–50.

9. Filatova EV, Zubkova NV, Novikova NA, Golitsina LN, Kuznetsov KV. Detection of parvovirus B19 markers in blood samples of donors. Zhurnal mikrobiologii, epidemiologii i immunobiologii 2010; (5): 67–70 (in Russian).

10. Belgesov NV, Vilyaninov VN, Romanenko SM, Tikhmenev IB, Popova NN Dynamics of identifying of bloodborne pathogen markers during testing of primary donor blood services division of the Military Medical Academy for the last 13 years. Vestnik gematologii 2014; X(4): 6–7 (in Russian).

11. Human Plasma (pooled and treated for virus inactivation). 2007:1646. European Pharmacopoeia. 6st ed. 2007. Available from: http://www.dandybooksellers.com/acatalog/European_Pharmacopoeia Supplement 6.1 Book .html.